{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:44:29Z","timestamp":1779090269544,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Myeloproliferative neoplasms (MPNs) are a heterogeneous group of disorders characterized by the abnormal proliferation of terminally differentiated myeloid cells. While cytogenetic abnormalities such as t(15;17) are documented in MPNs, the specific translocation resulting in NF1::SCAMP5 fusion has not been previously reported. Here we present a 69-year-old female patient with anemia and splenomegaly, exhibiting CALR exon 9 mutation (c.1099_1150del52) and JAK2 V617F negativity. Cytogenetic analysis revealed t(15;17)(q24;q11.2), distinct from the classical APL-associated t(15;17)(q22;q21), with RNA-Seq confirming a novel NF1::SCAMP5 fusion. Bone marrow biopsy showed MF-1 fibrosis and megakaryocyte depletion, deviating from typical primary myelofibrosis histology. The patient achieved stable disease post-ruxolitinib treatment. This case highlights a unique molecular-pathological profile, suggesting NF1::SCAMP5 may define a provisional MPN subtype with distinct genetic features, warranting further study to elucidate its clinical significance.<\/jats:p>","DOI":"10.3389\/fonc.2025.1600963","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T04:10:36Z","timestamp":1753071036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: A novel t(15;17)(q24;q11.2) translocation involving NF1::SCAMP5 fusion in a patient with myeloproliferative neoplasms"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuying","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yakun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guomin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16576","article-title":"Myelofibrosis biology and contemporary management","volume":"191","author":"Gangat","year":"2020","journal-title":"Br J Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242417383","article-title":"Myeloproliferative neoplasms: contemporary review and molecular landscape","volume":"24","author":"Mahmud","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04055-w","article-title":"Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States","volume":"99","author":"Verstovsek","year":"2020","journal-title":"Ann Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S208290","article-title":"t(15; 17) associated with primary myelofibrosis: a case report of an unusual clinical presentation and diagnostic dilemma","volume":"12","author":"Nadiminti","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-6703-2_20","article-title":"Recurrent cytogenetic abnormalities in myeloproliferative neoplasms and chronic myeloid leukemia","volume":"1541","author":"Swansbury","year":"2017","journal-title":"Methods Mol Biol (Clifton NJ)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3760\/cma.j.issn.0253-2727.2021.01.004","article-title":"Evaluation of the prognostic value of MIPSS70-plus in Chinese patients with primary myelofibrosis","volume":"42","author":"Yan","year":"2021","journal-title":"Zhonghua Xueyexue Zazhi"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.296","article-title":"Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid Malignancies and is accompanied by a mutation in the remaining allele in half of the cases","volume":"26","author":"Haferlach","year":"2012","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0147-4","article-title":"NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome","volume":"32","author":"Eisfeld","year":"2018","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41397-020-0149-2","article-title":"Prognostic role of SCAMP family in acute myeloid leukemia","volume":"20","author":"Qian","year":"2020","journal-title":"Pharmacogenom J"},{"key":"B13","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2022"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1038\/s41467-020-18691-3","article-title":"Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN","volume":"11","author":"Benlabiod","year":"2020","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute promyelocytic leukemia current treatment algorithms","volume":"11","author":"Yilmaz","year":"2021","journal-title":"Blood Cancer J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-198911","article-title":"Differentiation therapy of leukemia: 3 decades of development","volume":"113","author":"Nowak","year":"2009","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1521-6926(03)00062-8","article-title":"Molecular pathogenesis of acute promyelocytic leukaemia and APL variants","volume":"16","author":"Sirulnik","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03344-6","article-title":"Philadelphia chromosome-negative myeloproliferative neoplasms: clinical aspects and treatment options","volume":"115","author":"Gotoh","year":"2022","journal-title":"Int J Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1055\/a-1447-6667","article-title":"Current concepts of pathogenesis and treatment of philadelphia chromosome-negative myeloproliferative neoplasms","volume":"41","author":"Zeeh","year":"2021","journal-title":"Hamostaseologie"},{"key":"B20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0092-8674(01)00245-8","article-title":"NF1 tumor suppressor gene function: narrowing the GAP","volume":"104","author":"Cichowski","year":"2001","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63193","article-title":"Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice","volume":"123","author":"Chang","year":"2013","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ng0296-144","article-title":"Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells","volume":"12","author":"Bollag","year":"1996","journal-title":"Nat Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706123362404","article-title":"Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and Malignant myeloid disorders","volume":"336","author":"Side","year":"1997","journal-title":"New Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401240","article-title":"RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)","volume":"13","author":"Flotho","year":"1999","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat Genet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3287","article-title":"Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis","volume":"103","author":"Loh","year":"2004","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-198416","article-title":"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","volume":"114","author":"Loh","year":"2009","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202377","article-title":"Expression and prognostic analyses of SCAMPs in pancreatic adenocarcinoma","volume":"13","author":"Mao","year":"2021","journal-title":"Aging"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-21-07941.2000","article-title":"Novel SCAMPs lacking NPF repeats: ubiquitous and synaptic vesicle-specific forms implicate SCAMPs in multiple membrane-trafficking functions","volume":"20","author":"Fern\u00e1ndez-Chac\u00f3n","year":"2000","journal-title":"J Neurosci: Off J Soc Neurosci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"17012","DOI":"10.1038\/s41598-021-96440-2","article-title":"SCAMP2\/5 as diagnostic and prognostic markers for acute myeloid leukemia","volume":"11","author":"Yue","year":"2021","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/01616412.2022.2107754","article-title":"The role of SCAMP5 in central nervous system diseases","volume":"44","author":"Chen","year":"2022","journal-title":"Neurol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1600963\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T04:10:39Z","timestamp":1753071039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1600963\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":32,"alternative-id":["10.3389\/fonc.2025.1600963"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1600963","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"article-number":"1600963"}}